Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention

  • Naveen L. Pereira
    Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
  • Michael E. Farkouh
    Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada
  • Derek So
    University of Ottawa Heart Institute, Ottawa, Ontario, Canada
  • Ryan Lennon
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota
  • Nancy Geller
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
  • Verghese Mathew
    Department of Medicine, Loyola University, Maywood, Illinois
  • Malcolm Bell
    Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
  • Jang-Ho Bae
    Department of Internal Medicine, Division of Cardiology, Konyang University, Seo-gu, Taejon, South Korea
  • Myung Ho Jeong
    Heart Research Center, Chonnam National University, Gwangju, South Korea
  • Ivan Chavez
    Department of Cardiology, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
  • Paul Gordon
    Division of Cardiology, The Miriam Hospital, Providence, Rhode Island
  • J. Dawn Abbott
    Division of Cardiology, Rhode Island Hospital, Providence, Rhode Island
  • Charles Cagin
    Mayo Clinic Health System—La Crosse, La Crosse, Wisconsin
  • Linnea Baudhuin
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
  • Yi-Ping Fu
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
  • Shaun G. Goodman
    St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
  • Ahmed Hasan
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
  • Erin Iturriaga
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
  • Amir Lerman
    Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
  • Mandeep Sidhu
    Division of Cardiology, Department of Medicine, Albany Medical Center and Albany Medical College, Albany, New York
  • Jean-Francois Tanguay
    Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada
  • Liewei Wang
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota
  • Richard Weinshilboum
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota
  • Robert Welsh
    Department of Medicine, Mazankowski Alberta Heart Institute and University of Alberta, Edmonton, Alberta, Canada
  • Yves Rosenberg
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
  • Kent Bailey
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota
  • Charanjit Rihal
    Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota

書誌事項

タイトル別名
  • The TAILOR-PCI Randomized Clinical Trial

収録刊行物

  • JAMA

    JAMA 324 (8), 761-, 2020-08-25

    American Medical Association (AMA)

被引用文献 (7)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ